AhR Pharmaceuticals Announces the Issuance of an Australia Patent by the IP Australia
PRLog - March 31, 2015 - MADISON, Wis. -- An Australia patent has been issued to AhR Pharmaceuticals, Inc. by the IP Australia. The issued Australia patent covers the use of ITE and its structural analogs for cancer intervention and possible eradication in Australia.
ITE is an endogenous ligand or natural hormone for the aryl hydrocarbon receptor (AhR). Once bound to the receptor, ITE activates and drives the hormone-receptor complex in mediating a series of important biological and pharmacological processes in the body. Evidences collected by scientists from AhR Pharmaceuticals and a global research community as well have demonstrated ITE's potentials in treating cancer, obesity, and disorders related to imbalanced actions of immune systems.
"We are devoted to the development of a unique treatment and possible cure for cancer patients and this is the recognition by IP Australia of our efforts in innovation and invention in the area," said Dr. Jiasheng (Jason) Song, the Chief Scientific Officer of AhR Pharmaceuticals. "We will continue the efforts in innovation and protection of our important inventions," continued Dr. Song. "More importantly, our ongoing efforts may well lead to a better treatment or possible cure for our patients around the globe."
The patent (2010313622) is entitled "ITE for Cancer Intervention and Eradication". The inventor of the patent is Dr. Jiasheng (Jason) Song, the major inventor of ITE technologies and Chief Scientific Officer of AhR Pharmaceuticals (the assignee and owner of the issued Australia patent). To obtain the full text of the issued Australia patent, please follow (click) the link to the full-length patent document.
AhR Pharmaceuticals, Inc., with licensed ITE technologies as its foundational intellectual property from Wisconsin Alumni Research Foundation (WARF, the intellectual property manager of University of Wisconsin-Madison, a world-renowned research university), is devoted to the development of the natural hormone ITE and its structural analogs into an efficacious and sustainable but low side-effect therapeutic agent in intervention and possible eradication of cancer, obesity, and disorders due to imbalanced actions of immune systems. For more information on AhR Pharmaceuticals, Inc., its technologies, and research activities, please visit www.ahrpharma.com.
Read Full Story - An Australia Patent on ITE for Cancer Intervention and Eradication Issued to AhR Pharmaceuticals, Inc | More news from this source
Press release distribution by PRLog
An Australia Patent on ITE for Cancer Intervention and Eradication Issued to AhR Pharmaceuticals, Inc
March 31, 2015 at 07:00 AM EDT
